scholarly journals Implants as drug delivery devices for the treatment of eye diseases

2010 ◽  
Vol 46 (3) ◽  
pp. 585-595 ◽  
Author(s):  
Gisele Rodrigues da Silva ◽  
Sílvia Ligório Fialho ◽  
Rubens Camargo Siqueira ◽  
Rodrigo Jorge ◽  
Armando da Silva Cunha Júnior
Keyword(s):  
Drug Delivery ◽  
Posterior Segment ◽  
Sustained Drug Release ◽  
Ocular Tissues ◽  
Systemic Side Effects ◽  
Rapid Clearance ◽  
Effective Doses ◽  
Flowing Blood ◽  
High Doses ◽  
Drug Delivery Devices

The treatment of diseases affecting the posterior segment of the eye is limited by the difficulty in transporting effective doses of drugs to the vitreous, retina, and choroid. Topically applied drugs are poorly absorbed due to the low permeability of the external ocular tissues and tearing. The blood-retina barrier limits drug diffusion from the systemic blood to the posterior segment, thus high doses of drug are needed to maintain therapeutic levels. In addition, systemic side effects are common. Intraocular injections could be an alternative, but the fast flowing blood supply in this region, associated with rapid clearance rates, causes drug concentration to quickly fall below therapeutic levels. To obtain therapeutic levels over longer time periods, polymeric sustained-drug release systems implanted within the vitreous are being studied for the treatment of vitreoretinal disorders. These systems are prepared using different kinds of biodegradable or non-biodegradable polymers. This review aims to demonstrate the main characteristics of these drug delivery implants and their potential for clinical application.

Recent Advances in Non-Invasive Delivery of Macromolecules using Nanoparticulate Carriers System

2017 ◽  
Vol 23 (3) ◽  
pp. 440-453 ◽  
Author(s):  
Shadab Md. ◽  
Shadabul Haque ◽  
Ravi Sheshala ◽  
Lim Wei Meng ◽  
Venkata Srikanth Meka ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Oral Delivery ◽  
The Body ◽  
Administration Routes ◽  
Non Invasive ◽  
Current Formulation ◽  
Delivery Routes ◽  
Systemic Side Effects ◽  
Rapid Clearance

Background: The drug delivery of macromolecules such as proteins and peptides has become an important area of research and represents the fastest expanding share of the market for human medicines. The most common method for delivering macromolecules is parenterally. However parenteral administration of some therapeutic macromolecules has not been effective because of their rapid clearance from the body. As a result, most macromolecules are only therapeutically useful after multiple injections, which causes poor compliance and systemic side effects. Methods: Therefore, there is a need to improve delivery of therapeutic macromolecules to enable non-invasive delivery routes, less frequent dosing through controlled-release drug delivery, and improved drug targeting to increase efficacy and reduce side effects. Result: Non-invasive administration routes such as intranasal, pulmonary, transdermal, ocular and oral delivery have been attempted intensively by formulating macromolecules into nanoparticulate carriers system such as polymeric and lipidic nanoparticles. Conclusion: This review discusses barriers to drug delivery and current formulation technologies to overcome the unfavorable properties of macromolecules via non-invasive delivery (mainly intranasal, pulmonary, transdermal oral and ocular) with a focus on nanoparticulate carrier systems. This review also provided a summary and discussion of recent data on non-invasive delivery of macromolecules using nanoparticulate formulations.

Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

2016 ◽  
Vol 32 (3) ◽  
pp. 135-144 ◽  
Author(s):  
Pooja Bansal ◽  
Satpal Garg ◽  
Yograj Sharma ◽  
Pradeep Venkatesh
Keyword(s):  
Drug Delivery ◽  
Posterior Segment ◽  
Novel Therapies ◽  
Drug Delivery Devices

scholarly journals Nanoparticle–Cartilage Interaction: Pathology-Based Intra-articular Drug Delivery for Osteoarthritis Therapy

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Xu Li ◽  
Bingyang Dai ◽  
Jiaxin Guo ◽  
Lizhen Zheng ◽  
Quanyi Guo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Rational Design ◽  
Therapeutic Agents ◽  
Joint Disease ◽  
Pathological Features ◽  
Sustained Drug Release ◽  
Accurate Localization ◽  
Rapid Clearance ◽  
Solid Foundation ◽  
Multiple Modality

AbstractOsteoarthritis is the most prevalent chronic and debilitating joint disease, resulting in huge medical and socioeconomic burdens. Intra-articular administration of agents is clinically used for pain management. However, the effectiveness is inapparent caused by the rapid clearance of agents. To overcome this issue, nanoparticles as delivery systems hold considerable promise for local control of the pharmacokinetics of therapeutic agents. Given the therapeutic programs are inseparable from pathological progress of osteoarthritis, an ideal delivery system should allow the release of therapeutic agents upon specific features of disorders. In this review, we firstly introduce the pathological features of osteoarthritis and the design concept for accurate localization within cartilage for sustained drug release. Then, we review the interactions of nanoparticles with cartilage microenvironment and the rational design. Furthermore, we highlight advances in the therapeutic schemes according to the pathology signals. Finally, armed with an updated understanding of the pathological mechanisms, we place an emphasis on the development of “smart” bioresponsive and multiple modality nanoparticles on the near horizon to interact with the pathological signals. We anticipate that the exploration of nanoparticles by balancing the efficacy, safety, and complexity will lay down a solid foundation tangible for clinical translation.

scholarly journals Role of Micro Emulsion Based In-Situ Gelling System of Fluoroquinolone for Treatment of Posterior Segment Eye Diseases (PSED)

2020 ◽  
Vol 10 (3) ◽  
pp. 265-272
Author(s):  
Eram Fatima ◽  
Dr. Vivek
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Posterior Segment ◽  
Eye Diseases ◽  
Ocular Tissues ◽  
Micro Emulsion ◽  
Ophthalmic Drug ◽  
In Situ Gelling

The in situ drug delivery system and colloidal formulation like micro emulsion has potential to use in ocular delivery. Micro emulsion provides better permeation of drug through the membrane and provides improved bioavailability. The in situ drug delivery system decreases pre-corneal drainage, increase the contact time of formulation with eye and prolong the release in ocular tissues. Again, in situ gelling system has advantage of delivering accurate and reproducible quantities each time, against any already gelled formulations. To combine the benefits of these two dosage forms, micro emulsion based in situ gelling system can be developed as a novel vehicle for ophthalmic drug delivery. Endophthalmitis is an infection of intraocular fluids like vitreous humor and ocular tissues. To combat the disease, the formulation which provides sufficient concentration in posterior segment eye diseases (PSED) is required. Keywords: Posterior segment eye diseases, micro emulsion, drug delivery system, ocular, formulation.

Recent In Vitro and In Silico Advances in the Understanding of Intranasal Drug Delivery

2020 ◽  
Vol 26 ◽  
Author(s):  
John Chen ◽  
Andrew Martin ◽  
Warren H. Finlay
Keyword(s):  
Drug Delivery ◽  
In Silico ◽  
Local Drug Delivery ◽  
In Vivo Studies ◽  
Intranasal Drug Delivery ◽  
Nasal Sprays ◽  
In Silico Studies ◽  
Drug Delivery Devices

Background: Many drugs are delivered intranasally for local or systemic effect, typically in the form of droplets or aerosols. Because of the high cost of in vivo studies, drug developers and researchers often turn to in vitro or in silico testing when first evaluating the behavior and properties of intranasal drug delivery devices and formulations. Recent advances in manufacturing and computer technologies have allowed for increasingly realistic and sophisticated in vitro and in silico reconstructions of the human nasal airways. Objective: To perform a summary of advances in understanding of intranasal drug delivery based on recent in vitro and in silico studies. Conclusion: The turbinates are a common target for local drug delivery applications, and while nasal sprays are able to reach this region, there is currently no broad consensus across the in vitro and in silico literature concerning optimal parameters for device design, formulation properties and patient technique which would maximize turbinate deposition. Nebulizers are able to more easily target the turbinates, but come with the disadvantage of significant lung deposition. Targeting of the olfactory region of the nasal cavity has been explored for potential treatment of central nervous system conditions. Conventional intranasal devices, such as nasal sprays and nebulizers, deliver very little dose to the olfactory region. Recent progress in our understanding of intranasal delivery will be useful in the development of the next generation of intranasal drug delivery devices.

Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems

2020 ◽  
Vol 21 (7) ◽  
pp. 628-646
Author(s):  
Gülcem Altinoglu ◽  
Terin Adali
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Neurological Diseases ◽  
Sustained Drug Release ◽  
Physiochemical Properties ◽  
Conventional Drug ◽  
Health Care Burden ◽  
The Central Nervous System ◽  
Effective Drugs

Alzheimer’s disease (AD) is the most common neurodegenerative disease, and is part of a massive and growing health care burden that is destroying the cognitive function of more than 50 million individuals worldwide. Today, therapeutic options are limited to approaches with mild symptomatic benefits. The failure in developing effective drugs is attributed to, but not limited to the highly heterogeneous nature of AD with multiple underlying hypotheses and multifactorial pathology. In addition, targeted drug delivery to the central nervous system (CNS), for the diagnosis and therapy of neurological diseases like AD, is restricted by the challenges posed by blood-brain interfaces surrounding the CNS, limiting the bioavailability of therapeutics. Research done over the last decade has focused on developing new strategies to overcome these limitations and successfully deliver drugs to the CNS. Nanoparticles, that are capable of encapsulating drugs with sustained drug release profiles and adjustable physiochemical properties, can cross the protective barriers surrounding the CNS. Thus, nanotechnology offers new hope for AD treatment as a strong alternative to conventional drug delivery mechanisms. In this review, the potential application of nanoparticle based approaches in Alzheimer’s disease and their implications in therapy is discussed.

Anti-VEGFR2 Antibody-modified Micelle for Triggered Drug Delivery and Effective Therapy of Choroidal Neovascularization

2019 ◽  
Vol 16 (3) ◽  
pp. 258-265
Author(s):  
Kei Takahashi ◽  
Tomomi Masuda ◽  
Mitsunori Harada ◽  
Tadashi Inoue ◽  
Shinsuke Nakamura ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Choroidal Neovascularization ◽  
Pigment Epithelium ◽  
Drug Carrier ◽  
Retinal Pigment ◽  
Laser Coagulation ◽  
Antiangiogenic Agents ◽  
Drug Carrier System ◽  
Novel Drug ◽  
Drug Delivery Devices

Objective: This study aimed to examine whether DC101 (anti-VEGFR2 antibody)- modified micelles have applications as novel drug delivery devices, which allow small molecule antiangiogenic agents to deliver to angiogenic sites on a murine laser-induced choroidal neovascularization (CNV) model. Materials and Method: CNV was induced by photocoagulation on the unilateral eye of each mouse under anesthesia. Immediately after laser coagulation, E7974-loaded DC101-modified micelles and motesanib-loaded DC101-modified micelles were intravitreally administrated. Two weeks after photocoagulation, CNV was visualized using fluorescein-conjugated dextran (MW=2,000 kDa), and the CNV area was measured in retinal pigment epithelium (RPE)-choroidal flat mounts. Results: Intravitreal administration of both DC101-modified micelles loaded with E7974 at 2 µM and motesanib at 2 µM significantly reduced CNV area in the murine laser-induced CNV model at a clearly lower concentration than the effective dose of each agent. Conclusion: These results suggest that DC101-modified micelle might be effective drug carrier system for treating CNV and other ocular angiogenic diseases.

Sign in / Sign up

Export Citation Format

Share Document